Last $3.09 USD
Change Today +0.025 / 0.82%
Volume 23.8K
As of 10:54 AM 03/2/15 All times are local (Market data is delayed by at least 15 minutes).

enzo biochem inc (ENZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $6.13
52 Week Low
02/23/15 - $2.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ENZO BIOCHEM INC (ENZ)

enzo biochem inc (ENZ) Related Businessweek News

No Related Businessweek News Found

enzo biochem inc (ENZ) Details

Enzo Biochem, Inc., an integrated life sciences and biotechnology company, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Clinical Labs, Life Sciences, and Therapeutics. The Clinical Labs segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. This segment operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 35 patient service centers in New York and New Jersey; and a standalone laboratory in the New York, as well as a full-service phlebotomy, in-house logistics department, and information technology department. The Life Sciences segment manufactures, develops, and markets products and tools to life sciences, drug development, and clinical research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Therapeutics segment is involved in the research and development of therapeutic drug candidates in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

433 Employees
Last Reported Date: 10/9/14
Founded in 1976

enzo biochem inc (ENZ) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $555.5K
Co-Founder, President, Chief Financial Office...
Total Annual Compensation: $492.7K
Senior Vice President of Finance
Total Annual Compensation: $123.8K
Vice President of Corporate Development
Total Annual Compensation: $215.0K
Compensation as of Fiscal Year 2014.

enzo biochem inc (ENZ) Key Developments

Enzo Biochem Announces New Molecular Platform and First Product for Early Focus on Cervical Cancer Progression

Enzo Biochem Inc. announced the development of a new novel platform with consequential and broad application for detection of genotypic and phenotypic markers via flow cytometry, as well as the first product for its use addressing the cervical cancer testing market. The platform, FlowScript, allows for the multiplex analysis of cell function and identity in a single assay through the simultaneous examination of thousands of individual cells. The Enzo HPV E6/E7 assay, the first product developed for use with the FlowScript technology platform, addresses the $1 billion cervical cancer testing market. It enables the identification of certain upregulated oncogenes that can be indicative of cancer progression, allowing closer monitoring of patients exhibiting this condition. The new Enzo assay is designed to establish association between the expression of oncogenes and the progression of cervical cancer across a number of high risk HPV subtypes. Enzo Clinical Laboratory has submitted an application to the New York State Department of Health in advance of offering services based on the FlowScript assay. Upon receiving approval, Enzo will be the first clinical laboratory to provide this assay to physicians and other clinical labs, to which it will also make available key reagents for purchase. The FlowScript platform is the result of an integrated effort across the entire Enzo spectrum, and was developed along with key opinion leaders from both the life sciences and clinical fields. In effect, Enzo has positioned the new product as "a snapshot cell query" by allowing the analysis of mRNA transcript expression in individual cells in a mixed cell population. By studying whether a gene or a set of genes is turned on or off, rather than whether they are present, it is possible to obtain clinically relevant information at the single cell level. Such analysis provides comparative, actionable data examining disease versus healthy state. Currently Enzo has FlowScript based products under development for the identification of specific biomarkers related to cancer as well as those related to autoimmune diseases.FlowScript HPV E6/E7 contains controls for assuring operator consistency as well as a technical design to cover numerous aspects of the procedure, from the initial assay setup though the instrumentation settings and interpretation of the data. It improves efficiency by reducing the hands-on time required in other flow-based assays, in addition to being adaptable for use with virtually any flow cytometer on the market as well as any sample collection device. The FlowScript platform is anticipated to be further utilized for applications related to women’s health, oropharyngeal and anal cancer, infectious disease, immune-mediated disorders including autoimmunity, metabolic disorders, drug responsiveness, patient monitoring and drug development.

Enzo Biochem Inc. Announces Executive Changes

Enzo Biochem Inc. held its Annual Meeting of Shareholders on January 21, 2015. The company elected Elazar Rabbani as a Class III Director on the Board of Directors to hold office for a term of three years or until his successor.

Enzo Biochem Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015

Enzo Biochem Inc. Presents at The Trout Group 's Annual 1x1 Management Access Event, Jan-12-2015 . Venue: The Handlery Hotel, 351 Geary Street, Union Square, San Francisco, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZ:US $3.09 USD +0.025

ENZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
NanoString Technologies Inc $11.19 USD +0.68
NeoGenomics Inc $4.53 USD -0.01
Psychemedics Corp $16.17 USD -0.2392
Response Genetics Inc $0.63 USD +0.0056
WaferGen Bio-systems Inc $5.10 USD +0.12
View Industry Companies

Industry Analysis


Industry Average

Valuation ENZ Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.4x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZO BIOCHEM INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at